R. Robinson

Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer

F. Kabbinavar, M. Pegram, C. Emmanouilides, 2004, Techniques in Coloproctology.

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

G. Demetri, P. Sharma, A. Tolcher, 2021, Clinical Cancer Research.

Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil.

R. Williams, P. Smith, C. Humphrey, 1976, British journal of urology.

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

K. Gish, G. Demetri, Ying Huang, 2018, Experimental and Molecular Therapeutics.